hemostatic physiology and will help advance the knowledge of platelet response during stress, infection, and disease. In this short review we will focus on recent developments in the application of genomics to megakaryocyte and platelet biology. These new technologies have led to the discovery of causative mutations in several platelet disorders and have contributed to the molecular architecture that determines the "genetic profile" of platelets in health and disease.
| G ENE TI C REG UL ATI ON OF NORMAL MEG AK ARYOP OIE S IS
Platelets are shed into circulation by megakaryocytes, large polyploid cells that reside in the bone marrow and extend pro-platelet extensions into the bone marrow sinusoids. 3, 4 Once in the circulation, platelets survive for ~7 to 10 days. 5 Megakaryocytes produce ~100 billion platelets daily to maintain a normal range of circulating platelets of 150 to 400 000 platelets per microliter of blood. 3 During this process, megakaryocytes distribute their transcriptome and splicing machinery into platelets (see Figure 1 .1-2). 2 This is a much more nuanced model of thrombopoiesis than was originally appreciated. What was once thought to be non-functional vestigial RNA in platelets is now understood to be a highly regulated sorting process by which megakaryocytes invest platelets with mRNA during thrombopoiesis. 6 Despite the fact that they do not have a nucleus, platelets have been shown to have an active spliceosome and can process mRNA, which may play a role in platelet activation and thrombosis. 7, 8 Platelets have the ability to actively translate proteins required for thrombosis and inflammation with the mRNA and translation machinery derived from the megakaryocytes although the extent of these processes in normal hemostasis is not entirely clear. 9 These unique mRNA signatures may account for the fact that platelet function is highly variable, even among healthy individuals. Common mRNA signatures and miRNA profiles have been associated with differences in platelet reactivity between races as well as hereditary platelet disorders. 10, 11 Megakaryocytes are derived from pluripotent CD34+ hematopoietic stem cells (HSCs) 12 which give rise to common myeloid progenitors (CMP) and from them will differentiate into cells that are further committed down the lineage: the megakaryocyte-erythroid progenitor (MEP) which will give rise to megakaryocytes and/or erythroblasts (see Figure 1 ). Megakaryocytes mostly mature in the bone marrow, developing their characteristic polyploidy as they undergo endomitosis, a process by which the cells replicate their DNA without completing cell division. 13 During this maturation process, megakaryocytes increase their cytoplasmic volume and generate pro-platelet extensions into the bone marrow sinusoids and shed platelets into the circulation. 3 has been recently shown that the murine lung is a reservoir for hematopoietic progenitors and megakaryocytes, and a site for platelet biogenesis, 15 although the significance of these findings in human megakaryopoiesis is still unknown.
The commitment of MEPs toward differentiated megakaryocytes that produce platelets requires the cytokine thrombopoietin (TPO) and its receptor MPL, which signals downstream through JAK2, STAT3/5, and MAPK. 16 Rare mutations of the genes encoding thrombopoietin (THPO) and its receptor (MPL) result in congenital thrombocytopenia. 17 Several transcription factors have also been implicated in the differentiation process (see Table 1 ). 18 The combi- 
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| GENOMIC APPROACHES TO CONGENITAL PLATELET DISORDERS
The introduction of high throughput sequencing technology has significantly advanced the discovery of novel genes. Germline mutations in the genes encoding for hematopoietic transcription factors have been associated with congenital thrombocytopenia (see Table 1 ). Aberrant expression of these transcription factors may skew cellular differentiation and produce abnormal megakaryocytes, which go on to shed abnormal quality and/or quantity of platelets.
One of the first examples of the use of next generation sequencing in megakaryocyte disorders was the discovery of the gene responsible for gray platelet syndrome (GPS) by three different research groups. Mutations in NBEAL2 were determined to be the causative mutation in GPS by next-generation RNA sequencing of platelets, whole exome sequencing and traditional sequencing strategies, respectively. [37] [38] [39] More recently, ETV6 has been implicated in inherited thrombocytopenia using next-generation sequencing techniques.
40,41
The use of next generation sequencing has not only allowed for the discovery of highly penetrant mendelian thrombocytopenia such 43 The authors concluded unequivocally (P < 5 × 10 −228 ) that the compound (bi-allelic) inheritance of these noncoding SNPs together with a null mutation in RBM8A causes TAR syndrome although the mechanism by which these coinherited molecular defects reduce RBM8A transcription and protein expression is not known.
Another example is the use of WES in the discovery of de novo The discovery of these genes as causative mutations for inherited platelet defects demonstrates the immense capability for sequencing technology in identifying genetic causes of human disease.
Developing clinically useful applications of all these discoveries has been challenging because some of these genetic polymorphisms can be common and associated with only slightly increased or decreased disease risk. 45 However, using highly statistically powered studies, interpreting mechanisms and identifying causal alleles has become possible. As the ability to implement sequencing technologies in patient care became more readily accessible, clinicians are able now to screen and diagnose patients with inherited platelet disorders. Table 2 shows a current detailed description of inherited platelet disorders and their genetic causes. Furthermore, Astle et al. demonstrated that these rare mutations can be validated in high-powered GWAS studies. 45 
| THE NOVEL ROLE OF PLATELET RNA IN HEALTH AND DISEASE
Modern genomic techniques have made RNA sequencing feasible and cost effective. Over the last decade the field of megakaryocyte and platelet RNA has expanded significantly. For example, platelet reactivity has been associated with differential RNA expression profiles. 46 Platelet hyper-reactivity was associated with five-fold increase of VAMP8 mRNA transcript and increased protein levels of VAMP8. 46 VAMP8 is a v-SNARE protein that is involved in platelet granule secretion. The ability of platelets to aggregate is dependent on the release of the granule contents, and this process is facilitated by SNARE proteins at the plasma membrane.
47
VAMP8 mRNA has been shown to be differentially expressed in patients with coronary artery disease due to a SNP in the VAMP8
3'UTR (A->G rs1010). Furthermore, miR-96 is predicted to bind to 3'-UTR of VAMP8 mRNA and has been shown to be expressed in platelets. 48 Patients with hyperreactive platelets had a 4.8-fold increase in VAMP8 mRNA levels compared to patients with hyporeactive platelets. Interestingly, in a small number of study subjects, miR-96, which decreases VAMP8 mRNA was expressed at higher levels in platelets that were defined to be hyporeactive. This find- 
| CONCLUSIONS
The use of high throughput sequencing has significantly improved the ability to characterize genetic mechanisms of megakaryopoiesis and platelet formation and function, as well as to identify candidate genes for inherited platelet disorders and traits. 60 Initiatives like the 1000 Genomes Project, the International HapMap project, ENCODE project database, and other large-scale whole genome sequencing projects that link genotypes with health and social care records will be invaluable tools in understanding the link between gene mutations and corresponding disease. 61 While understanding the genetic variations that underlie platelet dysfunction is crucial for screening patients and developing a clear picture of the genetic landscape of normal megakaryopoiesis, sequencing alone does not always explain the molecular mechanism by which these genetic changes result in clinical phenotypes. More research into the functional consequence of these mutations is required to better understand the role that these genetic changes play. Functional studies will begin to elucidate the complex biology of megakaryopoiesis and thrombopoiesis and put these genetic mutations into the context of the larger hematopoietic system. 
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